This study is currently not recruiting participants.

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4

Study on Investigational Medicine for Cancer Treatment

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The first purpose is to test the safety of the investigational medicine at different dose levels. We want to find out what effects, good and/or bad, it has on your type of cancer. The second purpose of this study is to measure the levels of the investigational medicine in your blood at different times. The third purpose is to see whether the investigational medicine has any effect in the control of cancer.

Detailed description of study

The purpose of this study is to examine the safety and PK of ASG-22CE administered once weekly for 3 weeks of every 4 week cycle as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ovarian cancer,fallopian tube cancer,non-small cell lung cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and effects of an investigational medicine for treating metastatic urothelial cancer and other malignant solid tumors that express Nectin-4. The study aims to understand how different dose levels affect the cancer, whether the effects are beneficial or harmful. It also seeks to measure how much of the medicine is present in the blood at various times.

Participants will receive the investigational medicine once a week for three weeks in a four-week cycle. The study will monitor the impact of the medicine on cancer control and assess its safety. Participants will undergo regular blood tests to measure the levels of the medicine.

  • Who can participate: Individuals aged 18 and older with metastatic urothelial cancer or other malignant solid tumors that express Nectin-4 may be eligible to participate.
  • Study details: The investigational medicine will be administered once weekly for three weeks in each four-week cycle. Regular blood tests will be conducted to monitor the medicine levels.
Updated on 19 Feb 2024. Study ID: 1703776789 (ASG-22CE-13-2

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team